Cumberland Pharmaceuticals Inc.
209 10th Avenue
Suite 332
Nashville
Tennessee
37203
United States
Tel: 615-255-0068
Fax: 615-255-0094
Website: http://www.cumberlandpharma.com/
Email: mail@cumberlandpharma.com
261 articles about Cumberland Pharmaceuticals Inc.
-
Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update
11/10/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million . The company also recorded an additional $750,000 in revenue during the third quarter
-
Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use
8/18/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical Therapeutics.
-
Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update
8/11/2020
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology, provided a company update and announced second quarter 2020 financial results.
-
Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
8/4/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020.
-
Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients
7/20/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demon
-
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
5/26/2020
Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.
-
Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update
5/20/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results
-
Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results
5/15/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020
-
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
5/11/2020
Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company announces two new publications detailing the sustained in vitro potency of Vibativ® as part of a 7-year antimicrobial surveillance program.
-
Cumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities
4/28/2020
Includes Details About Company's Community Involvement, Ethical Marketing & Drug Safety
-
To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
4/7/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced an initiative to increase availability of Vaprisol® (conivaptan hydrochloride) injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic.
-
Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections
3/31/2020
Cumberland Pharmaceuticals Inc. announced a national initiative to support hospitals and clinics that use Caldolor® injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections.
-
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
3/23/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus.
-
Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019
3/18/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2019 financial results.
-
Cumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results
3/6/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today the rescheduling of its fourth quarter and annual 2019 financial results and company update from Wednesday, March 11, 2020 to Wednesday, March 18, 2020 after market close.
-
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results
3/4/2020
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2019 financial results and company update after the market closes on Wednesday, March 11 , 2020. A conference call and live Internet webcast will be held on Wednesday, March 11 , at 4:30 p.m. Eastern Time
-
Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
1/7/2020
Cumberland Pharmaceuticals Inc. announced the launch of Caldolor® Injection in a ready-to-use bag that may be administered without dilution for pain relief.
-
Cumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments
1/2/2020
A conference call and live Internet webcast will be held on Tuesday, January 7, at 4:30 p.m. Eastern Time to discuss the results.
-
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line
12/2/2019
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.
-
Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
11/12/2019
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology announced third quarter 2019 financial results with net revenues of $10.4 million, up 22% over the prior year quarter.